FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

BACKGROUND: Several progresses have been achieved for first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with Gem-NabP and FOLFIRINOX extensively used as standard first line regimens. However, the best second-line chemotherapy choice after progression is still not complete...

Descripción completa

Detalles Bibliográficos
Autores principales: Catalano, Martina, Conca, Raffaele, Petrioli, Roberto, Ramello, Monica, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585276/
https://www.ncbi.nlm.nih.gov/pubmed/33116881
http://dx.doi.org/10.2147/CMAR.S267393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585276/
https://www.ncbi.nlm.nih.gov/pubmed/33116881
http://dx.doi.org/10.2147/CMAR.S267393

Ejemplares similares